Telix Pharmaceuticals (TLX) Receivables - Net (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Receivables - Net for 3 consecutive years, with $129.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables - Net rose 41.68% year-over-year to $129.2 million; the TTM figure through Dec 2025 stood at $129.2 million (up 41.68% YoY), while the FY2025 annual figure was $129.2 million, up 48.63% from the prior year.
• Receivables - Net advanced to $129.2 million in Q4 2025 per TLX's latest filing, from $91.2 million in the prior quarter.
• Across five years, Receivables - Net topped out at $129.2 million in Q4 2025 and bottomed at $42.2 million in Q4 2023.
• Historically, Receivables - Net has averaged $87.5 million across 3 years, with a median of $91.2 million in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Net soared 116.25% — and 2025, when it surged 41.68%.
• Telix Pharmaceuticals' Receivables - Net stood at $42.2 million in 2023, then surged by 116.25% to $91.2 million in 2024, then soared by 41.68% to $129.2 million in 2025.
• Business Quant data shows TLX's Receivables - Net at $129.2 million in Q4 2025, $91.2 million in Q4 2024, and $42.2 million in Q4 2023.